What is Aspect Biosystems?
Aspect Biosystems is a pioneering privately held biotechnology firm at the forefront of 3D bioprinting and tissue engineering. Its proprietary Lab-on-a-Printer platform is instrumental in advancing fundamental biological research, disease modeling, therapeutic development, and regenerative medicine. The company actively pursues strategic partnerships with pharmaceutical, biotechnology firms, and academic institutions to develop physiologically relevant tissues, thereby accelerating the discovery and development of novel drugs and therapies.
How much funding has Aspect Biosystems raised?
Aspect Biosystems has raised a total of $215M across 4 funding rounds:
Other Financing Round
$1M
Series A
$20M
Series B
$115M
Unspecified
$79M
Other Financing Round (2018): $1M with participation from Genome British Columbia
Series A (2020): $20M led by Pallasite Ventures, Pangaea Ventures, Radical Ventures, and Rhino Ventures
Series B (2025): $115M supported by InBC Investment, Dimension Data, Pallasite Ventures, Novo Nordisk, Pangaea Ventures, JDRF T1D Fund, Radical Ventures, and Rhino Ventures
Unspecified (2026): $79M featuring Government of Canada
Key Investors in Aspect Biosystems
Pallasite Ventures
Pallasite Ventures is an agile venture capital firm based in Vancouver, Canada, that provides early-stage financing for high-growth companies across various industries, including tech and consumer products. The firm focuses on Seed and Series A investments, offering capital between $100k and $1.5m USD to support companies with strong leadership and market vision.
Pangaea Ventures
Pangaea Ventures is a leading venture capital firm specializing in hard tech, focusing on investments in start-up companies that utilize advancements in materials, chemistry, and biology to tackle significant global challenges. With over 25 years of experience, they aim to drive industrial transformation and promote sustainability through their portfolio.
Radical Ventures
Radical Ventures is a venture capital firm investing in bold entrepreneurs developing and applying artificial intelligence and other deep technologies to invent the future. Based in Toronto, Radical Ventures launched a US $350 Million fund in 2019 focused on Series A investments.
What's next for Aspect Biosystems?
The substantial enterprise-level backing indicates Aspect Biosystems is poised for significant scaling and market expansion. This strategic investment will likely fuel further research and development into its 3D bioprinting technologies, potentially enabling the creation of more complex and functional human tissues. The company's focus on strategic partnerships suggests an ongoing effort to integrate its platform into the drug discovery pipelines of major pharmaceutical players, positioning Aspect Biosystems as a key enabler in the future of therapeutic development and regenerative medicine.
See full Aspect Biosystems company page
